JUVMO (Tavapadon)

JUVMO (tavapadon) is a once-daily tablet approved by the US FDA on 25 September 2026 for the treatment of Parkinson’s disease in adults. It was studied both on its own in early Parkinson’s disease and as an add-on for people already taking levodopa who have “off” periods.

Tavapadon is a non-ergot dopamine agonist that acts as a selective partial agonist at the dopamine D1 and D5 receptors. AbbVie describes JUVMO as the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

In two 27-week studies without levodopa (TEMPO-1, 529 patients, and TEMPO-2, 304 patients), daily-living scores (MDS-UPDRS Part II) improved with JUVMO but worsened slightly or stayed flat with placebo. In TEMPO-3 (507 patients on levodopa), good “on” time without troublesome dyskinesia rose by 1.7 hours a day with JUVMO versus 0.6 hours with placebo, and “off” time fell by 1.9 hours versus 0.9 hours.

Other Parkinson’s medicines we help patients obtain include CREXONT (extended-release carbidopa/levodopa) and Inbrija (inhaled levodopa).

• Low blood pressure on standing (dizziness or fainting when getting up) occurred in 5% of patients not on levodopa and 8% of those on levodopa. Stand up slowly, especially in the first weeks.
• Impulse-control problems such as urges to gamble, spend, binge-eat or increased sexual urges can occur with dopamine agonists. Family members should report any such change; the doctor may lower the dose or stop JUVMO.
• Hallucinations or psychotic-like behaviour were seen in 3% (without levodopa) and 7% (with levodopa); the risk is higher at age 65 and over and with strong CYP3A inhibitors.
• Dyskinesia (involuntary movements) may start or worsen when JUVMO is added to levodopa (10% vs 2% with placebo).
• Most common side effects without levodopa: nausea (27%), headache, dizziness, tiredness, taste change, vomiting, dry mouth and anxiety. With levodopa: nausea (14%), dyskinesia, dizziness, headache, hallucinations and low blood pressure on standing.
• Many medicines interact through the liver enzyme CYP3A (for example the antifungal itraconazole and the herbal remedy St John’s wort). JUVMO itself speeds up CYP3A and can lower levels of some other drugs, so the full medicine list must be reviewed. There are no adequate data in pregnancy or breastfeeding.

Which pack is needed first?

Every patient starts with the JUVMO Titration Pack: six weekly blister cards of 0.25 mg and 1 mg tablets that raise the dose step by step from 0.25 mg to 3 mg over 40 days. From day 41 the usual dose is 5 mg once daily, taken with or without food, which the neurologist can raise in 5 mg steps about every two weeks to a maximum of 15 mg a day. Ongoing treatment uses bottles of 30 tablets of 5, 10 or 15 mg.

What documents do we need?

• Prescription from a neurologist stating the strength and titration plan
• Recent neurology notes confirming Parkinson’s disease and current medicines (including levodopa dose)
• Patient’s government photo ID

The order is confirmed only after the prescription is verified.

How should JUVMO be stored?

At room temperature, 20–25 °C (15–30 °C allowed for short periods). The FDA approval letter gives a shelf life of 36 months, so it travels without cold chain.

Is JUVMO available in India?

No. As of October 2026 JUVMO is approved only in the United States, where AbbVie expected it to reach pharmacies in October 2026. It is not approved by CDSCO, so a patient in India can obtain it only through named-patient import on a neurologist’s prescription.

Because treatment begins with a 40-day titration pack and then moves to a fixed daily strength, we plan the first two shipments together so there is no gap when the patient reaches the maintenance dose. Supply is through authorised US channels, in the patient’s name.

To ask about JUVMO cost in India or delivery time: Call +91 96548 60915, WhatsApp +91 93100 90915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA approval on 25 September 2026 (NDA 220415, new molecular entity).
• European Union and Japan: No approval or filing found as of October 2026.
• India: Not approved by CDSCO.

Sources:

• JUVMO US Prescribing Information (FDA, September 2026)
• FDA approval letter, NDA 220415
• AbbVie press release: FDA approves JUVMO (28 September 2026)

Information last checked: October 2026.

What is JUVMO prescribed for?

Parkinson’s disease in adults, either on its own or together with levodopa.

How does tavapadon work?

It acts selectively, as a partial agonist, on the D1 and D5 dopamine receptors in the brain.

How often is JUVMO taken?

Once a day, with or without food. If a dose is missed, take it the same day, but never take two doses to catch up.

Can JUVMO be used with levodopa?

Yes. In the TEMPO-3 study it was added to levodopa and increased good “on” time by about 1.1 hours a day more than placebo. Dyskinesia can increase, so the levodopa dose may need adjusting.

Who markets JUVMO?

AbbVie Inc., North Chicago, USA.

Has JUVMO been approved by the FDA?

Yes, on 25 September 2026.